Exact Sciences Cash Flow from Operating Activities 2010-2025 | EXAS

Exact Sciences cash flow from operating activities for the twelve months ending March 31, 2025 was $0.430B, a 92.99% increase year-over-year.

  • Exact Sciences annual cash flow from operating activities for 2024 was $0.211B, a 34.86% increase from 2023.
  • Exact Sciences annual cash flow from operating activities for 2023 was $0.156B, a 169.83% decline from 2022.
  • Exact Sciences annual cash flow from operating activities for 2022 was $-0.224B, a 118.67% increase from 2021.

Exact Sciences Cash Flow from Operating Activities 2010-2025 | EXAS

  • Exact Sciences annual cash flow from operating activities for 2024 was $0.211B, a 34.86% increase from 2023.
  • Exact Sciences annual cash flow from operating activities for 2023 was $0.156B, a 169.83% decline from 2022.
  • Exact Sciences annual cash flow from operating activities for 2022 was $-0.224B, a 118.67% increase from 2021.
Related Stocks
Company NameMarket
Cap
AstraZeneca (AZN)$243.4B
Amgen (AMGN)$156.3B
Gilead Sciences (GILD)$147.7B
Vertex Pharmaceuticals (VRTX)$100.1B
Bristol Myers Squibb (BMY)$97.3B
CSL (CSLLY)$85B
GSK (GSK)$80B
Regeneron Pharmaceuticals (REGN)$60B
Alnylam Pharmaceuticals (ALNY)$58B
Argenex SE (ARGX)$39.9B
BioNTech SE (BNTX)$27.1B
Insmed (INSM)$27B
Royalty Pharma (RPRX)$20.5B
Biogen (BIIB)$19.8B
Incyte (INCY)$16.8B
Illumina (ILMN)$15.4B
Genmab (GMAB)$14.7B
Genmab (GNMSF)$14.3B
Ascendis Pharma (ASND)$11.7B
BioMarin Pharmaceutical (BMRN)$11.1B
QIAGEN (QGEN)$10.9B
Moderna (MRNA)$10.4B
Exelixis (EXEL)$10.4B
Swedish Orphan Biovitrum (BIOVF)$10.3B
Verona Pharma American Depositary Share (VRNA)$9B
Bio-Techne Corp (TECH)$8.4B
Blueprint Medicines (BPMC)$8.3B
Roivant Sciences (ROIV)$8B
Halozyme Therapeutics (HALO)$7.7B
Guardant Health (GH)$7.5B